Sugi Predict

Sugi Predict / Compounds / SCHEMBL17396756

SCHEMBL17396756

SCHEMBL17396756

O=C(O)Cc1cc(C(F)(F)F)ccn1.[Li]CC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AGBL2 Q5U5Z8 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RXRA P19793 5/20 0.42
▸ RXRB P28702 5/20 0.42
▸ RXRG P48443 5/20 0.42
▸ NOS3 P29474 1/20 0.40
▸ NOS2 P35228 1/20 0.40
▸ GLS O94925 4/20 0.39
▸ MBOAT4 Q96T53 1/20 0.39
▸ AKR1B1 P15121 1/20 0.38
▸ RIOK2 Q9BVS4 1/20 0.38
▸ SORT1 Q99523 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ PSEN1 P49768 1/20 0.38
▸ PSEN2 P49810 1/20 0.38
▸ APH1B Q8WW43 1/20 0.38
▸ NCSTN Q92542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17396703 0.92 AGBL2 (0.47) AGBL2ALDH1A1GAAL3MBTL1RXRA
SCHEMBL29755981 0.92 AGBL2 (0.47) AGBL2ALDH1A1GAAL3MBTL1RXRA
Hydrochloric Acid SCHEMBL17653893 0.91 AGBL2 (0.46) AGBL2ALDH1A1GAAL3MBTL1RXRA
SCHEMBL17396700 0.91 AGBL2 (0.46) AGBL2ALDH1A1GAAL3MBTL1RXRA
SCHEMBL29894312 0.78 NOS3 (0.49) ALDH1A1GAAL3MBTL1NOS3NOS2
Lithium Ion SCHEMBL17396698 0.78 NOS3 (0.44) ALDH1A1GAAL3MBTL1NOS3NOS2
SCHEMBL3188772 0.78 NOS3 (0.49) ALDH1A1GAAL3MBTL1NOS3NOS2
SCHEMBL1427075 0.78 L3MBTL1 (0.55) ALDH1A1GAAL3MBTL1MBOAT4
SCHEMBL15505079 0.78 ALDH1A1 (0.48) ALDH1A1GAAL3MBTL1NOS3NOS2
SCHEMBL17396753 0.77 L3MBTL1 (0.54) ALDH1A1GAAL3MBTL1MBOAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-10-31 — — US disclosed
US-11958849-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-16 — — US disclosed
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-20 — — US disclosed
US-11370786-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-28 — — US disclosed
CN-107074805-B GLS1 inhibitors for the treatment of disease 德州大学系统董事会 2021-02-26 — — CN disclosed
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-12-31 — — US disclosed
US-10766892-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-09-08 — — US disclosed
EP-3677579-A1 HETEROCYCLIC GLS1 INHIBITORS Board of Regents, The University of Texas System (US) 2020-07-08 — — EP disclosed
EP-3164394-B1 GLS1 INHIBITORS FOR TREATING DISEASES UNIV TEXAS (US) 2020-04-01 — — EP disclosed
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-09-05 — — US disclosed
US-10344025-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-07-09 — — US disclosed
US-9809588-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-11-07 — — US disclosed
US-20170291895-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-10-12 — — US disclosed
EP-3164394-A2 GLS1 INHIBITORS FOR TREATING DISEASE Board of Regents, The University of Texas System (US) 2017-05-10 — — EP disclosed
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-14 — — US disclosed
WO-2016004404-A2 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344025-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-10766892-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-11370786-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLB1 AGBL2 606/4885ALDH1A1 766/4885GAA 139/4885
US-11958849-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20170291895-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 AGBL2 674/4885ALDH1A1 882/4885GAA 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.